Prevalence of antibodies against *Brucella* spp. in West Greenland polar bears (*Ursus maritimus*) and East Greenland muskoxen (*Ovibos moschatus*)

Christian Sonne[1,*], Emilie Andersen-Ranberg[1,2], Elisabeth L. Rajala[3], Jørgen Agerholm[4], Eva Bonefeld-Jørgensen[5,9], Jean-Pierre Desforges[1], Igor Eulaers[1], Kim Gustavson[1], Bjørn M. Jenssen[1,6,7], Anders Koch[8,9], Aqqalu Rosing-Asvid[10], Niels Martin Schmidt[1], Carsten Grøndahl[11], Jesper B. Mosbacher[1], Ursula Siebert[1,2], Morten Tryland[12], Gert Mulvad[9], Erik W. Born[9], Kristin Laidre[9,13], Øystein Wiig[14], Rune Dietz[1], Ulf Magnusson[3]

[1]Department of Bioscience, Arctic Research Centre, Faculty of Science and Technology, Aarhus University, P.O. Box 358, 4000 Roskilde, Denmark

[2]Institute for Terrestrial und Aquatic Wildlife Research, University of Veterinary Medicine Hannover, 25761 Büsum, Germany

[3]Department of Clinical Sciences, Division of Reproduction, Swedish University of Agricultural Sciences, P.O. Box 7054, 750 07 Uppsala, Sweden

[4]Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1870 Frederiksberg C, Denmark

[5]Department of Public Health, Centre for Arctic Health & Molecular Epidemiology, Aarhus University, 8000 Aarhus, Denmark

[6]Department of Biology, Norwegian University of Science and Technology, 7491 Trondheim, Norway

[7]Department of Arctic Technology, The University Centre in Svalbard, P.O. Box 156, 9171 Longyearbyen, Norway

[8]Department of Epidemiology Research & Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 2300 Copenhagen, Denmark

[9]Greenland Center for Health Research, Ilisimatusarfik, University of Greenland, 3905 Nuuk, Greenland

[10]Greenland Institute of Natural Resources, Kivioq 2, P.O. Box 570, 3900 Nuuk, Greenland

[11]Centre for Zoo and Wild Animal Health, Copenhagen Zoo, 2000 Frederiksberg, Denmark

[12]Department of Arctic and Marine Biology, The Arctic University of Norway, 9037 Tromsø, Norway

[13]Polar Science Center, Applied Physics Laboratory, University of Washington, Seattle, WA, USA

[14]Natural History Museum, University of Oslo, P.O. Box 1172 Blindern, 0318 Oslo, Norway

*Corresponding author: Professor Christian Sonne, DScVetMed, PhD, DVM, Vice President and Dipl. ECZM-EBVS (Wildlife Health), Aarhus University, Faculty of Science and Technology, Department of Bioscience, Frederiksborgvej 399, P.O. Box 358, DK-4000 Roskilde, Denmark. Tel. +45-30-78-31-72; Fax: +45-87-15-50-15; Email: cs@bios.au.dk

Abstract

Zoonotic infections transmitted from marine mammals to humans in European Arctic are of unknown significance, despite considerable potential for transmission due to local hunt and a rapidly changing environment. As an example, brucellosis may have significant impact on human health due to consumption of raw meat or otherwise contact with tissues and fluids of infected game species such as muskoxen and polar bears. Here we present serological results for Baffin Bay polar bears (*Ursus maritimus*) (n = 96) and North East Greenland muskoxen (*Ovibos moschatus*) (n = 32) for antibodies against *Brucella* spp. The analysis was a two-step trial initially using the Rose Bengal Test (RBT), followed by confirmative competitive enzyme-linked immunosorbent assays of RBT-positive samples. No muskoxen had antibodies against *Brucella* spp, while antibodies were detected in six polar bears (6.25%) rendering a seroprevalence in line with previous findings in other Arctic regions. Seropositivity was not related to sex, age or biometrics i.e. size and body condition. Whether the detected polar bear *Brucella* spp. antibodies found in polar bears were due to either prey spill over or true recurrent *Brucella* spp. infections is unknown. Our results therefore highlight the importance of further research into the zoonotic aspects of *Brucella* spp. infections, and the impact on wildlife and human health in the Arctic region.

Key words: Arctic; Humans; One Health; Zoonosis.

Introduction

The Arctic ecosystem is subject to several interacting anthropogenic stressors that cause cumulative stress in humans and wildlife, which may in turn lead to increased susceptibility to zoonotic infections (Atwood et al. 2017; Jenssen et al. 2015; Greer et al. 2008; Hueffer et al. 2011; Sonne 2010). In some human populations in the Arctic, it is common to consume raw or insufficiently heat-treated wildlife and game meat (Tryland et al. 2013). The importance of heat-treatment is exemplified by studies of toxoplasmosis in North America, where 80% of examined humans were seropositive in an Inuit community with dietary preference for raw meat, as opposed to 10% seropositivity within a local Cree population having dietary preference for cooked foods (Lévesque et al 2007; Messier et al. 2009). Marine mammals including polar bears, are an important food source for people in the Arctic, yet the burden of zoonotic pathogens in these species remains largely unknown in most Arctic regions. While human cases of trichinosis and digital mycoplasmosis ("seal-finger") are typically reported (Rodahl 1952; Tryland et al. 2013), the pathogen-spectrum has rarely been addressed by systematic studies. In addition to marine mammals, muskoxen are also an important food resource in some parts of the Arctic. For example, in Greenland alone more than 2,000 muskoxen and 150 polar bears are harvested annually (Piniarneq 2016). In addition to dietary exposure, Arctic hunters are in frequent physical contact with raw tissues and fluids of hunted wildlife, most often lacking any preventive measures against transmission of zoonotic pathogens. Information about the occurrence of wildlife transmitted zoonotic diseases in the Arctic parts of Europe is generally limited (Jenkins et al. 2013; Tryland et al. 2013), while it has been studied more intensively in Arctic Canada (Campagna et al. 2011; Goyette et al. 2014; Lévesque et al. 2007; Messier et al. 2012; Sampasa-Kanyinga et al. 2013).

Brucella spp. are zoonotic Gram-negative coccobacilli causing the disease brucellosis in humans and animals such as domestic ruminants, pigs, and dogs (Fraser 1991; Godfroid et al. 2011; Metcalf et al. 1994) and in Arctic mammals including polar bears (*Ursus maritimus*) and muskoxen

(*Ovibos moschatus*) (Atwood et al. 2017; Godfroid 2002; Godfroid et al. 2011; Nymo et al. 2011). Although brucellosis is rarely fatal, depending on the *Brucella* spp. and host, it may cause a range of pathological processes such as mastitis, abortion, orchitis, and osteomyelitis (Davis 1990; Enright 1990; Ross et al. 1994; Brew et al. 1999; Prenger-Berninghoff et al. 2008; Siebert et al. 2009, 2017). Specific species of *Brucella* are rarely reported for marine mammals since there exist no specific or validated serological tests (Godfroid 2002). Culture or DNA isolation and sequencing can overcome problems of cross-reactivity, but such samples are rarely available in relation to wildlife sample collection. The wide spread zoonotic *B. suis* biovar 4, also called "rangiferine brucellosis", has however been reported in muskoxen previously (Gates et al. 1984; Tomaselli et al. 2016).

As information regarding brucellosis in wildlife and the associated zoonotic risks are generally sparse for Greenland, the present study aimed at determining the seroprevalence of *Brucella* spp. exposure in West Greenland polar bears (*U. maritimus*) and East Greenland muskoxen (*O. moschatus*) to have a first assessment of the risk associated with handling, storage and consumption of these species.

Materials and methods

Sampling of polar bears

The sampling locality of polar bears from the West Greenland Baffin Bay subpopulation is shown in Figure 1. Serum samples ($n = 96$; Table 1) were obtained during a 5 years period (2009-2013) between Savissivik (ca. 76˚20´ N) and Uummannaq (ca. 70˚14´ N) (Laidre et al. 2012; SWG 2016). Polar bears were immobilised and handled according to standard procedures using 5-10 m Zoletil ® (200 mg/ml i.m.) from helicopter as described by Stirling et al. (1989). During immobilisation, blood samples were drawn from the femoral vein and a vestigial premolar (pm1) tooth was extracted for determination of individual age from analysis of incremental layers in the cementum. Blood samples were taken in plain vacutainers and following clotting, the blood was centrifuged at 1100g for 5 min.

106 The serum was pipetted off and transferred to cryovials, immediately frozen and stored at –20°C until
107 analysis. Standard body measurements (standard length and axillary girth in cm) were taken and total
108 body mass was estimated using the approach by Derocher and Wiig (2002). In the field, general body
109 condition of individual polar bears was visually estimated on a scale from 1 to 5 according to Stirling
110 et al. (2008), where 1 and 5 represent the leanest and most obese bears, respectively. According to
111 this scale, polar bears in categories 3 and 4 are in "good condition". The individual age estimations
112 were carried out by counting the cementum growth layer groups (GLGs) of the lower right rudimental
113 premolar after decalcification, sectioning (14 µm) and staining with toluidine blue as described by
114 Dietz et al. (1991). Polar bears were categorized as: cub of the year (COY), yearlings, two-year-old
115 cubs, sub-adults and adults. Adult males were those ≥6 years of age, and adult females were ≥5 years
116 of age according to Rosing-Asvid et al. (2002).
117
118 *Sampling of muskoxen*
119 Figure 1 shows the sampling locality of muskoxen. Serum samples from muskoxen (n = 32; Table 2)
120 were obtained during two surveys for the study of muskox spatial ecology in North East Greenland,
121 Zackenberg Valley, in 2013 and 2015. The muskoxen were immobilised and handled according to
122 standard procedures described in Mosbacher et al. (2016) and Schmidt et al. (2016). Briefly,
123 muskoxen were immobilized from the ground using a combination of etorphine, xylazine,
124 medetomidine, and ketamine. Doses were for a 200 kg female muskox were: 2 mg (0.01 mg/kg i.m.)
125 etorphine (Captivon 9.8 mg/ml; Wildlife Pharmaceuticals, White River, South Africa), 30 mg (0.15
126 mg/kg) xylazine (Rompun dry substance 500 mg; Bayer Animal Health, Denmark), 0.3 mg (0.0015
127 mg/kg) medetomidine (Zalopine 30 mg/ml; Orion Pharma Animal HealthDenmark) and 40 mg (0.2
128 mg/kg) ketamine (Ketaminol 100 mg/ml; MSD Animal Health, Denmark). Doses were supplemented
129 with sterile water for injection and absolute ethanol to prevent freezing. Resultant total volumes were
130 1.5 ml and a concentration of 20 % ethanol. Blood samples were taken from the jugular vein in plain

vacutainers and following clotting, the blood was centrifuged at 1100g for 5 min after which the serum was pipetted off and transferred to cryovials that were immediately frozen and stored at –20°C until analysis. The body condition score for muskoxen was determined by estimating the amount of soft tissue on rump, thorax and withers by palpation (Gerhart et al. 1996). Muskox age determination was based on horn development according to Olesen and Thing (1993). Only adult muskox individuals (aged 4 years of age or more) were handled and sampled.

Serological analyses

No specific or validated serological tests for *Brucella* infection in marine mammals have been developed and the detection of specific antibodies is based on tests used in terrestrial mammals (Godfroid 2002; Sonne et al. 2018). In an attempt to avoid problems of cross-reactivity and false-positives, two serological tests: the Rose Bengal Test (RBT) and the competitive-enzyme linked immuno-sorbent assay (C-ELISA), were performed to identify *Brucella* spp. antibodies in serum. According to the OIE Terrestrial Manual, the C-ELISA can eliminate some but not all false positive reactions due to cross-reacting bacteria such as Yersinia enterocolitica O:9 . According to the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (Eloit and Schmitt 2017), the RBT is recommended as a general purpose diagnostic test in all wildlife species while the C-ELISA appear to be useful for seroepidemiological surveys in wildlife (Stack et al. 1999).

All samples were initially screened with a commercial RBT (PrioCHECK Brucella Rose Bengal Test, Prionics AG, Zürich, Switzerland), according to the manufacturer's instructions. In brief, one drop of test serum (30 µl), and one drop of Rose Bengal antigen were transferred to the test circle on the slide and mixed thoroughly. The slide was rotated for 4 minutes whilst examined for agglutination. A positive and negative control were used in each test run. Positive samples were confirmed with C-ELISA (SVANOVA Biotech AB, Uppsala, Sweden) according to the manufacturer's instructions. In brief, 45 µl of sample dilution buffer was added into each well used

for serum samples, serum controls and conjugate controls, and 5 µl of positive, weak positive, and negative serum controls were added into appropriate wells. All control sera were run in duplicates. Five microliters of test sample were added in duplicates to the wells, and 50 µl of mAb-Solution were added to all wells used for controls and samples. The plates were incubated in 37ºC for 30 minutes. After incubation the plate was rinsed with buffer, and 100 µl Conjugate Solution were added into each well, followed by a second incubation at room temperature for 30 minutes. The plate was rinsed, and 100 µl Substrate Solution were added to each well and incubated for 10 minutes at room temperature before adding 50 µl Stop Solution to each well.

Optical density (OD) was assessed at 450 nm using a microplate photometer (air as blank) and the percent (%) of inhibition (PI) was calculated as:

$$PI = 100 - \frac{(OD\ samples\ or\ control\ \times 100)}{OD\ conjugate\ control}$$

Finally, the results were interpreted as negatives (PI < 30%) and positives (PI ≥ 30%). A sample was regarded as seropositive to Brucella when it tested positive in both RBT and C-ELISA.

Results

None of the muskoxen tested positive for *Brucella* spp. antibodies by the RBT, and were thus not analysed in the C-ELISA. Of the polar bears, 7 animals (7.3 %) tested positive in the RBT, while the C-ELISA confirmed that 6 (6.3%) of the polar bears were true seropositive (Figure 2). The six polar bears with antibodies against *Brucella* spp. included one adult male sampled in 2010, two adult females sampled in 2010 and 2012, two sub-adults sampled in 2011 (male) and 2012 (female) and one yearling (male) sampled in 2010. *Brucella* spp. positive sero-status thus appeared equally distributed among adults and younger polar bears in our cohort.

Discussion

180 Our findings are comparable with data for these species from other Arctic regions (Tryland et al.
181 2001; Rah et al. 2005; O'Hara et al. 2010; Godfroid, 2012). Tryland et al. (2001) found a
182 seroprevalence of 5.4% for *Brucella* spp. in 297 polar bears from Svalbard and the Barents Sea
183 collected from 1990-1998, while a seroprevalence ranging from 5-17% was found in polar bears from
184 Alaska (n = 500) and Canada (n = 275) collected between 2003 and 2006 and from 1982 to 1999,
185 respectively (O'Hara et al. 2010; Rah et al. 2005). As in our study, the serological screenings of polar
186 bears from Alaska did not shown any relationship between serostatus, sex and age of the bears (Rah
187 et al. 2005). In contrast to this, the study on polar bears from Beaufort Sea revealed a higher
188 seroprevalence in females than males (17 vs. 11%) and showed to be highest in animals aged 1-5
189 years (14%; n = 96; Rah et al. 2005).

190 The (sub)species of *Brucella* spp. bacteria involved and the source of infection in polar bears
191 have been disputed (Godfroid 2012). Indirect measures of brucellosis such as antibody tests, are in
192 general best supported by the isolation of *Brucella* spp., by which culture or genetic sequencing
193 renders a valid suggestion of taxonomic subcategorization. However, samples other than blood were
194 not available in the present study. Cross-reactivity in serologic assays between *Brucella* spp.
195 and *Yersinia enterocolitica* is well-documented (Ahvonen et al. 1969; Corbel and Dag 1973; Bundle
196 et al. 1984). However, in a study of seals and whales, both being polar bear prey, no cross reactivity
197 between *Brucella* spp. and *Y. enterocolitica* was found (Tryland et al. (1999). These data strongly
198 suggest that any observed antibody titres in muskoxen and polar bears of the present study were due
199 to *Brucella* spp. infection.

200 It is a general assumption that brucellosis is transmitted to polar bears through ingestion of
201 infected seals, whale or muskoxen (Tryland et al. 2001). In Alaska, *Brucella* spp. found in polar bears
202 were found likely to be of terrestrial origin (O'Hara et al. (2010). Altogether, this suggest that the
203 detected polar bear *Brucella* spp. antibodies found in the present investigation were due to either prey
204 spill over or true *Brucella* spp. infections (Fraser 1991; Tryland et al. 2001). Further studies are

205 therefore needed to address if *Brucella* spp. infections circulates among Greenland polar bears and
206 whether it is associated with any pathology. Such investigations would allow a better prediction of
207 *Brucella* spp. exposure and its significance for the health of North West Greenland polar bears.

208 Evidence of brucellosis in muskoxen is sparse. In consistency with our findings, an analysis of
209 132 muskoxen from North East Greenland in 1982 to 1983 revealed a seroprevalence for *Brucella*
210 spp. of 0% (Clausen and Hjort 1986). On the other hand, Nymo et al. (2016) found recurring *Brucella*
211 spp. antibody titres over time when analysing 52 muskoxen from Alaska (1982-2010). The
212 seropositive muskoxen were from a part of Alaska with a high prevalence of *Brucella* spp.
213 seropositive caribou (Zarnke et al. 2006). However, the North East Greenland muskox population is
214 geographically isolated, and thus no spill over from other Arctic ungulate populations is likely to take
215 place.

216 Serological screenings conducted in the North Atlantic and Greenland Sea indicate that
217 brucellosis has a wide geographical distribution among marine mammals including e.g. seal spp.
218 (Nielsen et al. 1996; Prenger-Berninghoff et al. 2008; Tryland et al. 1999, 2005). Greenland, with its
219 subsistence hunters and marine predator interactions (e.g. polar bears and seals), comprises a unique
220 opportunity to study the occurrence of zoonotic diseases in a One Health perspective while tying
221 together human and ecological and wildlife health. Brucellosis is in general a major public health
222 concern worldwide (Ross et al. 1996; Tryland et al. 2013). The presence of antibodies against
223 *Brucella* spp. in polar bears shows that these predators are exposed to the bacterium, although the
224 prevalence seems low (6.3%), but not if it is true infections or spill over from prey exposure. Only in
225 the case of true infections present a significant zoonotic potential for those who are handling or hunted
226 polar bears and consuming their meat. There was however no evidence of *Brucella* spp. exposure in
227 East Greenland muskoxen, which indicates that they are likely not affected by *Brucella* spp. infections
228 and thereby not presenting a risk in terms of being a source of zoonotic *Brucella* infection for handlers
229 and hunters.

Conclusions

Since all 32 analysed muskoxen were seronegative, the East Greenland population of the species seems to be free from brucellosis. 6.3% of the 96 polar bears analysed were seropositive either due to prey spill over or due to recurrent *Brucella* spp. infections. There was no clear association between seropositivity and age or biometric parameters i.e. size and body condition of polar bears. We suggest further studies on the distribution and taxonomic characterisation of *Brucella* spp. in Greenland, to better understand their potential harmful effects on wildlife populations as well as their zoonotic potential.

Compliance with Ethical Standards

According to national legislation for studies of polar bears all polar bear samples were collected with permission of the Government of Greenland´s Department of Fishery, Hunting and Agriculture (Nuuk). File number 66.24/06: 11 February 2009, 24 February 2010, 24 March 2011 (2011 and 2012), and 25 March 2013. Capture and handling of muskoxen in this study followed the guidelines of the American Society of Mammalogists (Sikes et al. 2011), and research permits were granted by the Greenlandic government (j.no. G13-029 and G15-019) and by the Greenlandic police (j. no 55se-50190-00153-15). No conflict of interest were reported.

Acknowledgements

Nordic Council of Ministers (NMR NORDEN) is acknowledged for financial support to the project Infectious Zoonotic Diseases Transmissible from harvested Wildlife to humans in the European Arctic (ZORRO). In addition, Greenland Institute of Natural Resources, 15. juni Foundation and the Zoological Garden of Copenhagen is acknowledged for funding to the Baffin Bay and Zackenberg

254 polar bear and muskoxen projects, respectively. Daniel Spelling Clausen is acknowledged for his
255 graphical support.

256 **References**

257 Ahvonen P, Jansson E, Aho K (1969) Marked cross-agglutination between Brucellae and a subtype
258 of *Yersinia enterocolitica*. Acta Pathol Microbiol Scand 75:291-295

259 Atwood TC, Duncan C, Patyk KA, Nol P, Rhyan J, McCollum M, McKinney MA, Ramey AM,
260 Cerqueira-Cézar CK, Kwok OCH, Dubey JP, Hennager S (2017) Environmental and behavioral
261 changes may influence the exposure of an Arctic apex predator to pathogens and contaminants.
262 Sci Reports 7:13193

263 Bradley M, Kutz SJ, Jenkins E, O'Hara TM (2005) The potential impact of climate change on
264 infectious diseases of Arctic fauna. Int J Circumpolar Health 64:468-477

265 Brew SD, Perrett LL, Stack JA, MacMillan AP, Staunton NJ (1999) Human exposure to Brucella
266 recovered from a sea mammal. Vet Rec 24:483

267 Bundle DR, Gidney MA, Perry MB, Duncan JR, Cherwonogrodzky JW (1984) Serological
268 confirmation of *Brucella abortus* and *Yersinia enterocolitica* O:9 O-antigens by monoclonal
269 antibodies. Infect Immun 46:389-393

270 Campagna S, Lévesque B, Anassour-Laouan-Sidi E, Côté S, Serhir B, Ward BJ, Libman MD, Drebot
271 MA, Makowski K, Andonova M (2011) Seroprevalence of 10 zoonotic infections in 2 Canadian
272 Cree communities. Diagn. Microbiol. Infect Dis 70:191-199

273 Clausen B, Hjort P (1986) Survey for antibodies against various infectious disease agents in
274 muskoxen (*Ovibos moschatus*) from Jameson Land, Northeast Greenland. J Wildlife Dis
275 22:264-266

276 Corbel MJ, Day CA (1973) Assessment of fluorescent antibody absorption procedures for
277 differentiation of the serological response to *Yersinia enterocolitica* serotype IX and *Brucella*
278 *abortus* in cattle. Br Vet J, 129: 67-71

279 Davis DS, Templeton JW, Ficht TA, Williams JD, Kopec JD, Adams LG (1990) *Brucella abortus* in
280 captive bison. I. Serology, bacteriology, pathogenesis, and transmission to cattle. J Wildl Dis
281 26:360-371
282 Derocher AE, Wiig Ø (2002) Postnatal growth in body length and mass of polar bears (*Ursus*
283 *maritimus*) at Svalbard. J Zool 256:343-349
284 Dietz R, Heide-Jørgensen MP, Härkönen T, Teilmann J, Valentin N (1991) Age determination of
285 European harbour seal (*Phoca vitulina L.*). Sarsia 76:17-21
286 Eloit M, Schmitt B (2017) Manual of diagnostic tests and vaccines for terrestrial animals 2017. World
287 Organisation for Animal Health, Paris, France. Available at: http://www.oie.int/international-
288 standard-setting/terrestrial-manual/
289 Enright FM, Araya LN, Elzer PH, Rowe GE, Winter AJ (1990) Comparative histopathology in
290 BALB/c mice infected with virulent and attenuated strains of *Brucella abortus*. Vet Immunol
291 Immunopathol 26:171-182
292 Ewalt DR, Payeur JB, Martin BM, Cummins DR, Miller WG (1994) Characteristics of a Brucella
293 species from a bottlenose dolphin (*Tursiops truncatus*). J Vet Diagn Invest 6:448-452
294 Fraser CM (1991) The Merck veterinary manual, a handbook of diagnosis, therapy, and disease
295 prevention, and control for the veterinarian, 7th Edition. Merck and Co., Inc., Rahway, New
296 Jersey. 1832 pp
297 Gates CC, Wobeser G, Forbes LB (1984) Rangiferine brucellosis in a muskox, *Ovibos moschatus*
298 *moschatus* (Zimmermann). J Wildl Dis 20: 233-234
299 Gerhart KL, White RG, Cameron RD, Russell DE (1996) Estimating Fat Content of Caribou from
300 Body Condition Scores. J Wildlife Manage 60:713-718
301 Godfroid J (2002) Brucellosis in wildlife. Rev Sci Tech 21:277-286
302 Godfroid J (2011) Are terrestrial mammals the source for exposure of polar bear to Brucella spp. in
303 Alaska? J Wildl Dis 47:479-480

304 Godfroid J, Scholz H, Barbier T, Nicolas C, Wattiau P, Fretin D, Whatmore AM, Cloeckaert A,
305 Blasco JM, Moriyon I, Saegerman C, Muma JB, Al Dahouk S, Neubauer H, Letesson JJ (2011)
306 Brucellosis at the animal/ecosystem/human interface at the beginning of the 21st century. Prev
307 Vet Med 102:118-131
308 Goyette S, Cao Z, Libman M, Ndao M, Ward BJ (2014) Seroprevalence of parasitic zoonoses and
309 their relationship with social factors among the Canadian Inuit in Arctic regions. Diagn
310 Microbiol Infect Dis 78:404-410
311 Greer A, Ng V, Fisman D (2008) Climate change and infectious diseases in North America: the road
312 ahead. CMAJ 178:715-722
313 Handeland K, Tengs T, Kokotovic B, Vikoren T, Ayling RD, Bergsjo B, Siguroardottir O, Bretten T
314 (2014) *Mycoplasma ovipneumoniae* - A primary cause of severe pneumonia epizootics in the
315 Norwegian muskox (*Ovibos moschatus*) population. PLoS One 9:e106116
316 Hueffer K, O'Hara TM, Follmann EH (2011) Adaptation of mammalian host-pathogen interactions
317 in a changing arctic environment. Acta Vet Scand 53:17
318 Hunt TD, Ziccardi MH, Gulland FM, Yochem PK, Hird DW, Rowles T, Mazet JA (2008) Health
319 risks for marine mammal workers. Dis Aquat Org 81:81
320 Jenkins EJ, Castrodale LJ, de Rosemond SJ, Dixon BR, Elmore SA, Gesy KM, Hoberg EP, Polley L,
321 Schurer JM, Simard M (2013) Tradition and transition: parasitic zoonoses of people and
322 animals in Alaska, northern Canada, and Greenland. Adv Parasitol 82:33-204
323 Jenssen BM, Dehli Villanger G, Gabrielsen KM, Bytingsvik J, Ciesielski TM, Sonne C, Dietz R
324 (2015) Anthropogenic flank attack on polar bears: Interacting consequences of climate warming
325 and pollutant exposure. Frontiers Ecol 3:1-7
326 Kersh GJ, Lambourn DM, Raverty SA, Fitzpatrick KA, Self JS, Akmajian AM, Massung RF (2012)
327 *Coxiella burnetii* infection of marine mammals in the Pacific Northwest, 1997–2010. J Wildlife
328 Dis 48:201-206

329 Koch A, Svendsen CB, Christensen JJ, Bundgaard H, Vindfeld L, Christiansen CB, Kemp M,
330 Villumsen S (2010) Q fever in Greenland. Emerg Infect Dis 16:511-513
331 Kutz S, Bollinger T, Branigan M, Checkley S, Davison T, Dumond M, Elkin B, Forde T, Hutchins
332 W, Niptanatiak A, Orsel K (2015) Cross-Canada Disease Report: *Erysipelothrix rhusiopathiae*
333 associated with recent widespread muskox mortalities in the Canadian Arctic. Can Vet J
334 56:560-563
335 Laidre KL, Born EW, Gurarie E, Wiig Ø, Stern H, Dietz R (2012) Females roam while males patrol:
336 Comparing movements of adult male and adult female polar bears during the springtime
337 breeding season. Proc R Soc B 280:1752
338 Lévesque B, Messier V, Bonnier-Viger Y, Couillard M, Côté S, Ward BJ, Libman MD, Gingras S,
339 Dick D, Dewailly É (2007) Seroprevalence of zoonoses in a Cree community (Canada). Diag
340 Microbiol Infect Dis 59:283-286
341 Matope G, Muma JB, Toft N, Gori E, Lund A, Nielsen K, Skjerve E (201) Evaluation of sensitivity
342 and specificity of RBT, c-ELISA and fluorescence polarisation assay for diagnosis of
343 brucellosis in cattle using latent class analysis. Vet Immunol Immunopathol 141:58-63
344 McDermott J, Grace D, Zinsstag J (2013) Economics of brucellosis impact and control in low-income
345 countries. Rev Sci Tech 32:249-261
346 McDonald WL, Jamaludin R, Mackereth G, Hansen M, Humphrey S, Short P, Taylor T, Swingler J,
347 Dawson CE, Whatmore AM, Stubberfield E, Perrett LL, Simmons G (2006) Characterization
348 of a Brucella sp strain as a marine-mammal type despite isolation from a patient with spinal
349 osteomyelitis in New Zealand. J Clin Microbiol 44:4363-4370
350 Messier V, Levesque B, Proulx JF, Rochette L, Libman MD, Ward BJ, Serhir B, Couillard M, Ogden
351 NH, Dewailly É, Hubert B, Déry S, Barthe C, Murphy D, Dixon B (2009) Seroprevalence of
352 *Toxoplasma gondii* among Nunavik Inuit (Canada). Zoonoses Public Health 56:188-197

353 Messier V, Lévesque B, Proulx J, Rochette L, Serhir B, Couillard M, Ward B, Libman M, Dewailly
354 É, Déry S (2012) Seroprevalence of seven zoonotic infections in Nunavik, Quebec (Canada).
355 Zoonoses and Public Health 59: 107-117.
356 Metcalf HE, Luchsinger DW, Ray WC (1994) Brucellosis. In: Handbook of Zoonoses, Beran, G.W.
357 and J.H. Steele (Eds.). CRC Press, Boca Raton, Fla, pp: 9-39
358 Mosbacher JB, Michelsen A, Stelvig M, Hendrichsen DK, Schmidt NM (2016) Show me your rump
359 hair and I will tell you what you ate - The dietary history of muskoxen (*Ovibos moschatus*)
360 revealed by sequential stable isotope analysis of guard hairs. Plos One 11: e0152874
361 Nielsen O, Nielsen K, Stewart RE (1996) Serologie evidence of Bruceila spp. exposure in Atlantic
362 walruses (*Odobenus rosmarus*) and ringed seals (*Phoca hispida*) of Arctic Canada. Arctic
363 49:383-386
364 Nymo IH, Tryland M, and Godfroid JG (2011) A review of *Brucella* infection in marine mammals
365 with special emphasis on *Brucella pinnipedialis* in the hooded seal (*Cystophara cristata*). Vet
366 Res 42:93
367 Nymo IH, Beckmen K, Godfroid J (2016) Anti-Brucella Antibodies in Moose (*Alces alces gigas*),
368 Muskoxen (*Ovibos moschatus*), and Plains Bison (*Bison bison bison*) in Alaska, USA. J
369 Wildlife Dis 52:96-99
370 Olesen CR, Thing H (1989) Guide to field classification by sex and age of the muskox. Can J Zool
371 67:1116-1119
372 O'Hara TM, Holcomb D, Elzer P, Estepp J, Perry Q, Hagius S, Kirk C (2010) Brucella species survey
373 in polar bears (*Ursus maritimus*) of northern Alaska. J Wildlife Dis 46:687-694
374 Parkinson AJ, Butler JC (2005) Potential impacts of climate change on infectious diseases in the
375 Arctic. Int J Circumpolar Health 64:478-486
376 Piniarneq (2016) Hunting information and registration. www.businessingreenland.gl, 25pp

377 Prenger-Berninghoff E, Siebert U, Stede M, Weiß R (2008) Incidence of *Brucella* species in marine
378 mammals of the German North Sea. Dis Aquat Organ 81:65-71
379 Rah H, Chomel BB, Follmann EH, Kasten RW, Hew CH, Farver TB, Garner GW, Amstrup SC (2005)
380 Serosurvey of selected zoonotic agents in polar bears (*Ursus maritimus*). Vet Record 156:7-13
381 Rodahl K (1952) "Spekk-Finger" or Sealers Finger. Arctic 5: 235-240
382 Rosing-Asvid A, Born EW, Kingsley MCS (2002) Age at sexual maturity of males and timing of the
383 mating – season of polar bears (*Ursus maritimus*) in Greenland. Polar Biol. 25:878-883
384 Ross HM, Foster G, Reid RJ, Jahans KL, MacMillan AP (1994) Brucella species infection in sea-
385 mammals. Vet Rec 134:359
386 Ross HM. Jahans KL, MacMillan AP, Reid RJ, Thompson PM, Foster G (1996) Brucella species
387 infection in North Sea seal and cetacean populations. Vet Rec 138:647-648
388 Sampasa-Kanyinga H, Lévesque B, Anassour-Laouan-Sidi E, Côté S, Serhir B, Ward BJ, Libman
389 MD, Drebot MA, Makowski K, Dimitrova K. 2013. Zoonotic infections in communities of the
390 James Bay Cree territory: An overview of seroprevalence. Can J Infect Dis Med Microbiol
391 24:79-84
392 Schmidt NM, van Beest FM, Mosbacher JB, Stelvig M, Hansen LH, Grøndahl C (2016) Ungulate
393 movement in an extreme seasonal environment: Year-round movement patterns of high-arctic
394 muskoxen. Wildlife Biol 22:253-267
395 Siebert U, Prenger-Berrninghof E, Weiss R (2009) Regional differences in bacteria flora in harbour
396 porpoises from the North Atlantic: environmental effects. J Appl Microbiol 106:329-337
397 Siebert U, Rademaker M, Ulrich SA, Wohlsein P, Ronnenberg K, Prenger-Berninghoff E (2017)
398 Bacterial microbiota in harbor seals (*Phoca vitulina*) from the North Sea of Schleswig-Holstein,
399 Germany, around the time of morbillivirus and influenzy epidemics. J Wildlife Dis 53:201-214
400 Sikes RS, Gannon WL (2011) Guidelines of the American Society of Mammalogists for the use of
401 wild mammals in research. J Mammal 92:235-253

Sohn AH, Probert WS, Glaser CA, Gupta N, Bollen AW, Wong JD, Grace EM, McDonald WC (2003) Human neurobrucellosis with intracerebral granuloma caused by a marine mammal Brucella spp. Emerg Infect Dis 9:485-488

Sonne C (2010) Health effects from long-range transported contaminants in Arctic top predators: An integrated review based on studies of polar bears and relevant model species. Environ Int 36:461-491

Sonne C, Andersen-Ranberg E, Rajala EL, Agerholm JS, Bonefeld-Jørgensen E, Desforges JP, Eulaers I, Jenssen BM, Koch A, Rosing-Asvid A, Siebert U, Tryland M, Mulvad G, Härkönen T, Acquarone M, Nordøy ES, Dietz R, Magnusson U (2018) Seroprevalence for Brucella spp. in Baltic ringed seals (Phoca hispida) and East Greenland harp (*Pagophilus groenlandicus*) and hooded (*Cystophora cristata*) seals. Vet Immunol ImmunoPathol 198:14-18

Stack JA, Perrett LL, Brew SD, MacMillan AP (1999) Competitive ELISA for bovine brucellosis suitable for testing poor quality samples. Vet Rec 145:735-736

Stirling I, Spencer C, Andriashek D (1989) Immobilization of polar bears (*Ursus maritimus*) with Telazol in the Canadian Arctic. J. Wildlife Dis 25:159-168

Stirling I, Thiemann GW, Richardson E (2008) Quantitative support for a subjective fatness index for immobilized polar bears. J Wildl Manage 72:568-574

SWG [Scientific Working Group to the Canada-Greenland Joint Commission on Polar Bear] (2016) Re-Assessment of the Baffin Bay and Kane Basin Polar Bear Subpopulations: Final Report to the Canada-Greenland Joint Commission on Polar Bear. 31 July 2016: x + 636 pp. https://www.gov.nu.ca/sites/default/files/baffin_bay_kane_basin_polar_bear_cgjcpb_report_summary_eng.pdf

Tomaselli M, Dalton C, Duignan PJ, Kutz S, van der Meer F, Kafle P, Surujballi O, Turcotte C, Checkley S (2016) Contagious ecthyma, rangiferine brucellosis, and lungworm infection in a muskox (*Ovibos moschatus*) from the Canadian Arctic, 2014. J Wildl Dis 52: 719-724

427 Tryland M, Kleivane L, Alfredson A, Kjeld M, Arnason A, Godfroid J (1999) Evidence of *Brucella*
428 infection in marine mammals in the North Atlantic Ocean. Vet Rec 144:588-592
429 Tryland M, Derocher AE, Wiig Y, Godfroid J (2001) Brucella sp. antibodies in polar bears from
430 Svalbard and the Barents Sea. J Wildl Dis 37:523-531
431 Tryland M, Sørensen KK, Godfroid J (2005) Prevalence of *Brucella pinnipediae* in healthy hooded
432 seals (*Cystophora cristata*) from the North Atlantic Ocean and ringed seals (*Phoca hispida*)
433 from Svalbard. Vet Microbil 105:103-111
434 Tryland M, Nesbakken T, Robertson L, Grahek-Ogden D, Lunestad BT (2013) Human pathogens in
435 marine mammal meat – a northern perspective. Zoonoses Public Health 61:377-394
436 Whatmore AM, Dawson CE, Groussaud P, Koylass MS, King AC, Shankster SJ, Sohn AH, Probert
437 WS, McDonald WL (2008) Marine mammal Brucella genotype associated with zoonotic
438 infection. Emerging Infectious Diseases 14:517-518

TABLES

Table 1. Year and biometrics (weight, body condition and standard length) for the 96 West Greenland polar bears immobilised and serum sampled during 2009-2013. COYs: cub of the year, F: females, M: males. Weight: estimate body weight based on Derocher and Wiig (2002). Condition: body condition (1-5). SL: Standard length. Blanks: age/sex groups not immobilised and sampled.

	2009		**2010**		**2011**		**2012**		**2013**	
	Mean±SD (n)	Min-Max (n)	Mean±SD (n)	Min-Max (n)	Mean±SD (n)	Min-Max (n)	Mean±SD (n)	Min-Max (n)	Mean±SD (n)	Min-Max (n)
COYs F										
Weight (kg)					21.65 (1)	21.65 (1)	18.00 (1)	18.00 (1)		
Condition (1-5)					3 (1)	3 (1)	2 (1)	2 (1)		
SL (cm)					93 (1)	93 (1)	89.5 ± 3.54 (2)	87-92 (2)		
COYs M										
Weight (kg)							17.09±5.12 (2)	13.5-20.7 (2)		
Condition (1-5)							3 (2)	3-3 (2)		
SL (cm)							87±5.66 (2)	83-91 (2)		
Yearlings F										
Weight (kg)			72.6±14.9 (2)	62-83.2 (2)	85±13.4 (2)	75.5-94.5 (2)	108.6±10.8 (2)	100.9-116.2 (2)	57.8 (1)	57.8 (1)
Condition (1-5)			3 (2)	3-3 (2)	3 (2)	3-3 (2)	3 (3)	3-3 (2)	3 (1)	3 (1)
SL (cm)			140.5±10.6 (2)	133-148 (2)	155.5±3.54 (2)	153-158 (2)	159±2.8 (2)	157-161 (2)	134 (1)	134 (1)
Yearlings M										
Weight (kg)			104.5±21.9 (2)	89-120 (2)	117.9±17.9 (2)	105.1-130.5 (2)				
Condition (1-5)			3 (2)	3-3 (2)	3 (2)	3-3 (2)				
SL (cm)			154±9.9 (2)	147-161 (2)	167.5±4.9 (2)	164-171 (2)				
Two-year-old F										
Weight (kg)	131.2±29.6 (2)	110.3-152.1 (2)	160.7 (1)	160.7 (1)	115.9 (1)	115.9 (1)				
Condition (1-5)	3 (2)	3-3 (2)	3 (1)	3 (1)	3 (1)	3 (1)				
SL (cm)	169.5±12.0 (2)	161-178 (2)	179.0 (1)	179.0 (1)	167.0 (1)	167.0 (1)				
Two-year-old M										
Weight (kg)	149.2 (1)	149.2 (1)			182.6 (1)	182.6 (1)	136.3±43.4 (2)	105.6-167.0 (2)		
Condition (1-5)	3 (1)	3 (1)			3 (2)	3-3 (2)	3 (2)	3 (2)		
SL (cm)	184 (1)	184 (1)			182 (1)	182 (1)	169±15.6 (2)	158-180 (2)		
Subadults F										
Age (years)	4 (1)	4 (1)	3 (1)	3 (1)	2.5±0.71 (2)	2-3 (2)	3 (2)	3-3 (2)		
Weight (kg)	132.7 (1)	132.7 (1)	147.5 (1)	147.5 (1)	131±11.3 (2)	123-139 (2)	191.2±46.9 (2)	158-224.4 (2)		
Condition (1-5)	3 (1)	3 (1)	3 (1)	3 (1)	2.5±0.71 (2)	2-3 (2)	2 (2)	2-2 (2)		
SL (cm)	182 (1)	182 (1)	174 (1)	174 (1)	174.5±6.36 (2)	170-179 (2)	188±24 (2)	171-205 (2)		
Subadults M										
Age (years)	4 (1)	4 (1)	3.25±1.26 (4)	2-5 (4)	4±1 (3)	3-5 (3)	5 (1)	5 (1)		

Weight (kg)	214.0 (1)	214.0 (1)	192.1±32.1 (4)	161.7-234.1 (4)	232.9±12.7 (3)	225-247.6 (3)	283.2 (1)	283.2 (1)		
Condition (1-5)	3 (1)	3 (1)	2.5±0.58 (4)	2-3 (4)	3±1 (3)	2-4 (3)	2 (1)	2 (1)		
SL (cm)	198 (1)	198 (1)	192.5±8.96 (4)	184-205 (4)	208±12.49 (3)	194-218 (3)	222 (1)	222 (1)		
Adult F										
Age (years)	9.6±5.13 (5)	6-17 (5)	13.25±3.73 (8)	5-16 (8)	9.7±3.9 (11)	5-15 (11)	7.44±2.46 (9)	5-12 (9)	9 (1)	9 (1)
Weight (kg)	194.9±19.0 (5)	170.1-221.6 (5)	229.2±30.4 (8)	176.6-260 (8)	208±15.8 (11)	172.8-227.9 (11)	201.4±27.1 (9)	150.4-232.6 (9)	221.2 (1)	221.2 (1)
Condition (1-5)	2.4±0.55 (5)	2-3 (5)	2.63±0.52 (8)	2-3 (8)	2.8±0.6 (11)	2-4 (11)	2.55±0.53 (9)	2-3 (9)	2 (1)	2 (1)
SL (cm)	202.8±2.39 (5)	199-205 (5)	198.8±4.8 (8)	194-207 (8)	198.3±5.62 (11)	188-207 (11)	196.7±6.34 (9)	184-203 (9)	205 (1)	205 (1)
Adult M										
Age (years)	11.4±6.6 (5)	6-20 (5)	15.7±7 (3)	9-23 (3)	11.7±5.7 (7)	6-24 (7)	13.2±3.56 (5)	9-17 (5)	9 (1)	9 (1)
Weight (kg)	379.0±66.3 (5)	283.8-439.0 (5)	358.1±74.6 (3)	276.2-422.1 (3)	382.6±61.3 (7)	270.7-438.8 (7)	409.6±28 (5)	378.4-451.5 (5)	331 (1)	331 (1)
Condition (1-5)	2.8±1.1 (5)	1-4 (5)	2.33±0.58 (3)	2-3 (3)	2.57±0.53 (7)	2-3 (7)	3.4±0.55 (5)	3-4 (5)	3 (1)	3 (1)
SL (cm)	237.6±8.88 (5)	229-250 (5)	233.7±13.8 (3)	218-244 (3)	235.7±6.82 (7)	228-248 (7)	236±11.8 (5)	221-248 (5)	217 (1)	217 (1)

444

445 **Table 2.** Biological information of the 32 East Greenland muskoxen immobilised and serum sampled
446 in 2013 and 2015. Males were not immobilised and sampled in 2015. F: females, M: males

447

		2013 Mean±SD (n)	Min-Max	**2015** Mean±SD (n)	Min-Max
Adult F	Weight	188.5±16.7 (13)	146-209	197.5±12.2 (14)	171.3-211.3
	Condition	4±0	4-4	4±0	4-4
Adult M	Weight	268±18 (5)	246-292	-	
	Condition	4±0	4-4		

448

449 **FIGURE LEGENDS**

450

451 **Figure 1.** Map showing the sample sites, numbers and years for North West Greenland polar bears
452 and North East Greenland muskoxen included in the present study.

453

454 **Figure 2.** Seroprevalence for *Brucella* spp. among 96 North West Greenland polar bears sampled
455 2009-2013 based on RBT (n = 96) and subsequently confirmed by C-ELISA analyses (n = 6).

FIGURES



FIGURE 1



459

460 **FIGURE 2**